webinar cme top

CLICK HERE for free ICUS webinars

Basic and advanced CEUS training with free CME credit


CLICK HERE for virtual exhibits


CLICK HERE to register for live ICUS educational programs

With free CME, resuming Fall 2020


webinar cme bottom

covid 19 ceus

The global COVID-19 pandemic presents unprecedented challenges for the ultrasound community, which often finds itself on the front lines of the battle against this deadly virus. Infected patients are often critically ill and require urgent bedside imaging of their lungs, heart and other organ systems. In this setting, ultrasound is uniquely capable of providing a safe, reliable and relatively inexpensive means of imaging these vulnerable patients, and the addition of an ultrasound enhancing agent may be essential for evaluating heart function.


ICUS is supporting the ultrasound community and patients worldwide by gathering the latest medical literature and training resources addressing the safe and optimal delivery of ultrasound services during this rapidly evolving global crisis. These resources include protocols for protecting personnel, disinfecting equipment, safely administering ultrasound contrast or enhancing agents, and appropriately imaging the heart, lungs and other organ systems in highly vulnerable patients.


CLICK HERE to learn more. Additional submissions may be sent to info@icus-society.org


The ICUS family extends heartfelt wishes for your safety and health as we come together to defeat this deadly virus.


Global Contrast-Enhanced Ultrasound (CEUS)

Click on any country shaded in orange to see the commercially available agent(s).
 

(Agent(s) commercially available)

 

 

(No agent commercially available at this time)

 

* See package inserts for approved indications. Note that this “Global CEUS” map lists certain ultrasound contrast agents under different product names (i.e., Lumason/SonoVue and Definity/Luminity). ICUS will update this map as additional agents are approved throughout the world.

 

ICUS does not endorse or recommend the use of any ultrasound contrast agent or other medical product. In addition, ICUS does not warrant the accuracy of information provided in package inserts or herein. Medical decisions are the sole responsibility of health care providers and their patients, who are encouraged to carefully evaluate all potential risks and benefits associated with the use of any medical product or procedure including ultrasound contrast agents and (CEUS).


 

Contrast-Enhanced Ultrasound Can Pinpoint Lung Findings Unique to COVID-19

Contrast-Enhanced Ultrasound Can Pinpoint Lung Findings Unique to COVID-19

May 21, 2019 — Diagnostic Imaging
By Whitney J. Palmer
Throughout the COVID-19 pandemic, diagnostic imaging has been used to manage and monitor the progression of pneumonia associated with the virus. New evidence gathered with contrast-enhanced lung ultrasound, however, now shows patients exhibit patterns in the lung that are not typically found with pneumonia.
Citing three cases with male patients, Italian researchers, led by Gino Soldati, M.D., from the diagnostic and interventional ultrasound unit at Valle del Serchio General Hospital in Lucca, Italy, (read more…)

Contrast ultrasound reveals unique COVID-19 lung findings

Contrast ultrasound reveals unique COVID-19 lung findings

May 21, 2020 — AuntMinnie
By Theresa Pablos, AuntMinnie staff writer
Contrast-enhanced ultrasound scans revealed patterns in the lung not typically associated with pneumonia in three Italian patients with COVID-19, according to a report published on May 12 in the Journal of Ultrasound in Medicine.
The three male patients in the study were all admitted to a hospital in Italy with laboratory-confirmed COVID-19 and pneumonia-like symptoms. However, when doctors performed contrast-enhanced ultrasound scans on the patients, they found large perfusion defects in a (read more…)

Contrast‑enhanced ultrasound imaging of the liver: a review of the clinical evidence for SonoVue and Sonazoid

Contrast‑enhanced ultrasound imaging of the liver: a review of the clinical evidence for SonoVue and Sonazoid

May 18, 2020 — Abdominal Radiology
Abstract
Contrast-enhanced ultrasound (CEUS) has become an established modality in various clinical indications for liver diseases. SonoVue®, a pure blood pure agent, and Sonazoid®, which exhibits an additional Kupffer phase, are contrast agents approved for liver imaging. This review discusses and compares the current clinical evidence for these two ultrasound contrast agents in the characterization and detection of focal liver lesions in the non-cirrhotic and cirrhotic liver, as well as for the use in interventional procedures (read more…)

Ultrasound Enhancing Agents In the COVID-19 Era: Protocols, Safety, & Impact

Ultrasound Enhancing Agents In the COVID-19 Era: Protocols, Safety, & Impact

Webinar – Northwest Imaging Forums (CME credits available – see below)
Presented by: Jonathan R. Lindner1, Thomas R. Porter2, Michelle Bierig3
1. Oregon health and Sciences University; 2. University of Nebraska Medical Center; 3. Hillcrest Hospital South
The current COVID-19 pandemic has raised interest in whether there are changes in either the role or safety of ultrasound enhancing agents (UEAs) in echocardiography. This Webinar from experts in the practice of contrast echocardiography will address:

The impact of UEAs in patients with known or suspected (read more…)

Registry on Performance of contrast echocardiography in confirmed COVID-19 patients

Registry on Performance of contrast echocardiography in confirmed COVID-19 patients

European Association of Cardiovascular Imaging (EACVI)
Echocardiography is often used for the detection of cardiac dysfunction and identification of LV thrombus induced by COVID-19. However, there is no data regarding the usefulness and safety of echo contrast in COVID-19 patients. This registry has been designed to answer this crucial issue.
You are kindly asked to enter your own data every time you scan a patient.
To start entering data, please visit: https://www.surveymonkey.com/r/8BYFFTQ

Contrast-Enhanced Ultrasound for the Evaluation of Renal Transplants

Contrast-Enhanced Ultrasound for the Evaluation of Renal Transplants

May 15, 2020 — Journal of Ultrasound in Medicine
Abstract
Contrast-enhanced ultrasound has emerged as a useful imaging modality for the evaluation of the transplant kidney. Advantages over traditional imaging modali¬ties such as computed tomography and magnetic resonance imaging include the ability to visualize a lesion’s enhancement pattern in real time, the lack of neph-rotoxicity, and relatively low cost. Potential uses of contrast-enhanced ultrasound include characterization of solid and cystic transplant renal masses, assessment for pyelonephritis and identification of its complications, and (read more…)

Filling of Fine and Core Biopsy Needles With the Contrast Agent Sulfur Hexafluoride

Filling of Fine and Core Biopsy Needles With the Contrast Agent Sulfur Hexafluoride

Ex Vivo and in vitro Evaluation of Ultrasound Needle Visibility
May 12, 2020 — Journal of Ultrasound in Medicine
Abstract
Objectives
To investigate whether the ex vivo and in vitro ultrasound visibility of fine needles (FNs) and core biopsy needles (CNBs) can be improved by filling them with an ultrasound contrast agent.
Methods
After needle filling with the contrast agent sulfur hexafluoride, punctures with FNs and CBNs were recorded in the B‐mode and contrast‐specific imaging mode (10 observations in each of the 4 groups). Recordings were (read more…)

Contrast‐Enhanced Ultrasound in Patients With COVID‐19

Contrast‐Enhanced Ultrasound in Patients With COVID‐19

Pneumonia, Acute Respiratory Distress Syndrome, or Something Else?
May 12, 2020 — Journal of Ultrasound in Medicine
Abstract
Coronavirus disease 2019 spiepr132 (COVID‐19) represents a very heterogeneous disease. Some aspects of spiepr132 COVID‐19spiepr132 pneumonia question the real nature of ground glass opacities and its consolidative lesions. It has been hypothesized that spiepr132 COVID‐19spiepr132 lung involvement could represent not only a viral effect but also an immune response induced by the infection, causing epithelial/endothelial lesions and coagulation disorders. We report 3spiepr146 cases of spiepr132 (read more…)

Real time ultrasound molecular imaging of prostate Cancer with PSMA-targeted Nanobubbles

Real time ultrasound molecular imaging of prostate Cancer with PSMA-targeted Nanobubbles

Apr 26, 2020 — Nanomedicine
Abstract
Contrast-enhanced ultrasound with microbubbles has shown promise in detection of prostate cancer (PCa), but sensitivity and specificity remain challenging. Targeted nanoscale-contrast agents with improved capability to accumulate in tumors may result in prolonged signal enhancement and improved detection of PCa with ultrasound. Here we report nanobubbles (NB) that specifically targets prostate specific membrane antigen (PSMA) overexpressed in PCa. The PSMA-targeted-NB (PSMA-NB) were utilized to simultaneously image dual-flank PCa (PSMA-positive PC3pip and PSMA-negative PC3flu) to examine whether (read more…)

Limited added value of contrast-enhanced ultrasound over B-mode for the subtyping of hepatocellular adenomas

Limited added value of contrast-enhanced ultrasound over B-mode for the subtyping of hepatocellular adenomas

April 24, 2020 — European Journal of Radiology
Abstract
Purpose
To compare the features of hepatocellular adenoma subtypes (HCAs) in B-mode and contrast-enhanced ultrasound (CEUS).
Method
Thirty-three patients (31 women [94%] and two men [6%], median age [Q1-Q3] 43.5 years old [35-51]) with 44 pathologically proven and subtyped HCAs (including 29 inflammatory HCAs [I-HCA] and 15 HNF1- α inactivated HCAs [H-HCA]) who underwent CEUS were included. The features of HCA on B-mode and CEUS were independently reviewed by two radiologists and compared between HCA subtypes.
Results
I-HCAs (read more…)